Axim Biotechnologies Inc. (OTCMKTS:AXIM) Expands Its Research Division With New Lab In San Diego

Axim Biotechnologies Inc. (OTCMKTS:AXIM), an investment company of Medical Marijuana Inc. (OTCMKTS:MJNA), has announced the expansion of its research division by establishing an ultra-modern laboratory in San Diego’s biotechnology hub. The company has also indicated that Dr. Sergei Svarovsky will be the leader of its oncology research group as a Chief Scientific Officer and the founder of Sapphire Biotech Inc.

The new lab in San Diego in a prime location

The Medical Marijuana CEO, Stuart Titus, indicated that the state of the art laboratory in San Diego, California, is a huge step for AXIM in bringing its research in-house. It will also help the company is continuing its innovative scientific discoveries expeditiously. Titus added the company was delighted and anticipated more innovations from the research team.

The new AXIM research lab is equipped fully, and research is expected to be conducted by its oncology-research group. It sits in a prime location next to some of the leading biotech companies in the world. The density of the biotech companies in the San Diego area gives AXIM the ability to enhance the speed, as well as access to its research because of the proximity of vital chemistry and analytical services as well as biology equipment.

Svarovsky to lead the new lab

Dr. Svarovsky will be in charge of activities at the laboratory as the Chief Scientific Officer. Besides overseeing activities in the new lab, he will also lead the research and product development initiatives of Sapphire. Svarovsky has Physical Chemistry Masters from the Novosibirsk State University as well as a Doctor of Philosophy in Physical Organic Chemistry. He is also a Research Fellow of NIH’s National Cancer Institute and has received the NHI Fellow Award for Research Excellence because of his innovations.

John Hurmoller II, the CEO of AXIM Biotech, indicated that the company pivoted recently into a new oncology-focused entity. Therefore through the new lab and Svarivsky’s experience and leadership, they expect to continue making innovative discoveries through the talented research team and ultramodern resources.